The problem with Progesterone trial was reliance on subjective target points. 50% of progesterone patients had positive function outcomes. Only problem is so did placebo patients.
All eyes on biomarkers like non convulsive seizures in our trial.
The problem with Progesterone trial was reliance on subjective...
Add NEU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
$22.14 |
Change
1.150(5.48%) |
Mkt cap ! $2.829B | |||
| Open | High | Low | Value | Volume |
| $21.50 | $22.44 | $21.50 | $13.15M | 598.8K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 437 | $22.12 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $22.15 | 8325 | 7 |
View Market Depth
| Last trade - 16.10pm 17/07/2024 (20 minute delay) ? |
| NEU (ASX) Chart |